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Edited by Stuart FergusonAbstract The ubiquitous heterodimeric nitric oxide (NO)
receptor soluble guanylate cyclase (sGC) plays a key role in var-
ious signal transduction pathways. Binding of NO takes place at
the prosthetic heme moiety at the N-terminus of the b1-subunit of
sGC. The induced structural changes lead to an activation of the
catalytic C-terminal domain of the enzyme and to an increased
conversion of GTP into the second messenger cyclic GMP
(cGMP). In the present work we selected and substituted diﬀer-
ent residues of the sGC heme-binding pocket based on a sGC
homology model. The generated sGC variants were tested in a
cGMP reporter cell for their eﬀect on the enzyme activation
by heme-dependent (NO, BAY 41-2272) stimulators and heme-
independent (BAY 58-2667) activators. The use of these experi-
mental tools allows the enzyme’s heme content to be explored in
a non-invasive manner. Asp44, Asp45 and Phe74 of the b1-subunit
were identiﬁed as being crucially important for functional en-
zyme activation. b1Asp45 may serve as a switch between diﬀerent
conformational states of sGC and point to a possible mechanism
of action of the heme dependent sGC stimulator BAY 41-2272.
Furthermore, our data shows that the activation proﬁle of
b1IIe145 Tyr is unchanged compared to the native enzyme, sug-
gesting that Tyr145 does not confer the ability to distinguish be-
tween NO and O2. In summary, the present work further
elucidated intramolecular mechanisms underlying the NO-
and BAY 41-2272-mediated sGC activation and raises questions
regarding the postulated role of Tyr145 for ligand discrimination.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Soluble guanylate cyclase, the intracellular receptor for the
biological messenger nitric oxide (NO), is a heterodimer that
consists of an a- and a heme-containing b-subunit. The pros-Abbreviations: sGC, soluble guanylate cyclase; NO, nitric oxide;
RLUs, relative light units; WT, wild-type; cGMP, cyclic GMP; n.d.,
not detectable
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doi:10.1016/j.febslet.2006.06.079thetic heme group is coordinated to the b-subunit via the axial
ligand His105, and the recently identiﬁed heme-binding motif
Tyr135, Ser137 and Arg139 (Y–x–S–x–R) [1–6]. The enzyme is
activated upon binding of its physiological activator, NO, to
the reduced heme moiety, which strongly increases the conver-
sion of GTP to cyclic GMP (cGMP). This second messenger
regulates various eﬀector systems such as phosphodiesterases,
ion channels and protein kinases. Thus, the NO/cGMP path-
way modulates physiological processes including vasodilata-
tion, neurotransmission and platelet aggregation [7,8]. Due
to its ubiquitous nature, the pathogenesis of various disease
states, especially of the cardiovascular system, has been linked
to aberrant activation of the NO/sGC/cGMP pathway [7–9].
In recent years, several compounds have been identiﬁed that
activate the enzyme in a NO independent fashion [10–13]. The
ﬁrst group of compounds comprises the NO-independent,but
heme-dependent soluble guanylate cyclase (sGC) stimulators
such as YC-1 and BAY 41-2272, which show a strong syner-
gism upon combination with NO and a loss of activation after
removal or oxidation of the prosthetic heme moiety [11,14,15].
In contrast, the second group of activators , such as BAY 58-
2667, preferentially activate the heme-deﬁcient/oxidized en-
zyme by binding to the unoccupied heme-binding site or by
replacing the weakly bound oxidized heme [3,13]. Hemeoxi-
dants such as ODQ, increase the proportion of oxidized sGC
leading to the observed potentiation of the BAY 58-2667-in-
duced sGC activation [3].
Recently, we developed a cGMP reporter cell line that al-
lows a non-invasive intracellular screening of mutants aﬀecting
the activation of sGC in an intact intracellular environment
without the need of further puriﬁcation [16]. Thus we were able
to identify the b1-subunit residues Tyr135 and Arg139 as crucial
counterparts of the propionic acid groups in the heme moiety
[3]. Until then only b1His105 was known to be involved in heme
binding [1,2]. These two newly identiﬁed amino acids, together
with b1Ser137, comprise the unique heme binding motif Tyr–x–
Ser–x–Arg, as was recently conﬁrmed by crystallization studies
of a prokaryotic heme protein with structural homology to the
sGC heme binding domain [3–6].
Based on the X-ray structure of the H-NOX domain of
Thermoanaerobacter tengcongensis (1U55.pdb) and a 19% se-
quence identity to the heme-binding domain of rat sGC, we
built a homology model of the rat sGC domain (b1, 1–195).
In agreement with published data, the model suggests thatblished by Elsevier B.V. All rights reserved.
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b1-subunit [5,6]. Hydrophobic amino acids lining the distal
heme pocket in close proximity to the heme moiety might also
be involved in signal transduction mechanisms upon binding
of NO via hydrophobic interactions. Moreover, a recent study
showed that introduction of a polar Tyr into the heme-binding
fragment of sGC results in an oxygen binding enzyme [17]. The
aim of the present work was to characterize the impact of
b1Asp45, the neighboring b1Asp44, the hydrophobic residues
lining the heme-binding pocket and the introduction of a polar
residue on sGC activation. Therefore, the relevant amino acids
were exchanged and the sGC variants were screened within
their cytosolic environment using the cellular GMP readout
system.2. Materials and Methods
2.1. Compounds
BAY 58-2667 (4-[((4-carboxybutyl){2-[(4-phenethyl-benzyl)oxy]-
phenethyl}amino)methyl[benzoic]acid) and BAY 41-2272 (5-cyclopro-
pyl-2-[1-(2-ﬂuoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-
4-ylamine) were synthesized as described [18,19]. DEA/NO (2-(N,
N-diethylamino)-diazenolate-2-oxide) and ODQ (1H-(1,2,4)-oxadiaz-
ole-(4,3-a)-quinoxalin-1-one) were purchased from Alexis Biochemi-
cals (San Diego, USA). All other chemicals of analytical grade were
obtained from Sigma (Taufkirchen, Germany).
2.2. Homology molecular model of rat sGC heme binding domain
The model is based on the X-ray structure of the oxygen-binding
heme domain of a protein from T. tengcongensis (1U55.pdb) [5].
Although sequence identity is low (19%), a homology model of the
heme binding domain of rat sGC (1–195) was built using the protein
structure prediction program Prime (Prime, Schro¨dinger LLC, Port-
land, OR, USA) and reﬁned by multiple minimizations (for result see
Fig. 1). Model quality was ensured using the analysis tools imple-
mented in Prime. These include residue-based energies, close con-
tacts, bond lengths, angles, dihedrals and missing hydrogen bonds.
The quality of our model was satisfactory in all respects therefore it
was used for the selection of substitutions and the determination of
amino acid positions with respect to the heme domain. In addition
to model building, a BLAST search was performed and a subsequent
multiple sequence alignment, carried out by using the program MULT-
LAIN [20], revealed several conserved amino acids. Fig. 1B was pre-
pared by using the program ESPRIPT [21].
2.3. Mutagenesis
Mutagenesis was performed using the QuickChange-XL site-direc-
ted mutagenesis kit (Stratagene, La Jolla, USA) according to manufac-
turer’s instructions. Primers used to generate the desired substitutions
are listed in Table 1. The accuracy of the substitutions was veriﬁed by
sequencing (Invitek, Berlin, Germany).
2.4. Transient transfection
The transient cotransfection of the a1- and b1-subunit was per-
formed by a method recently described [3]. Brieﬂy, cGMP reporter
cells were seeded on 96-well microtiter plates at a density of 10,000
cells per well and were cultured for 1 day at 37 C, 5% CO2. Cells were
cotransfected with a transfection mixture containing 36 ng a1- and
36 ng b1-plasmid, 0.12 ll Plus
 reagent and 0.6 ll of Lipofect-
AMINE (Invitrogen, Carlsbad, USA) in 100 ll Opti-MEM serum-Fig. 1. (A) Structural model of the heme-binding domain of rat sGC, based
showing the orientation of the heme-binding motif Tyr–x–Ser–x–Arg and resid
of selected eukaryotic and prokaryotic heme-binding proteins. Numbering c
bonds with b1Arg139 are highlighted in yellow. Green shading indicates hy
binding motif Tyr–x–Ser–x–Arg. The name of the sequence is followed by i
shown above the alignment. Arrows indicate predicted b-strands, coils reprefree medium (Invitrogen). After 3 h, 100 ll serum-containing medium
was added and cells were incubated for 24 h at 37 C, 5% CO2 to
ensure optimal protein expression.
2.5. cGMP reporter cell line and cGMP readout
The generation of the cGMP reporter cell and the cGMP readout
has been previously described [3,16]. Brieﬂy, for the determination of
the sGC activation proﬁle, transiently transfected cGMP reporter cells
were incubated with various concentrations of the sGC stimulator,
BAY 41-2272 or sGC activator, BAY 58-2667 alone or in presence
of DEA/NO or ODQ for 15 min at 37 C, 5% CO2. 3-Isobutyl-1-meth-
ylxanthin (0.2 mM) was used to prevent cGMP degradation by endog-
enous PDEs. The bioluminescence readout was initiated by application
of 10 mM CaCl2 containing buﬀer and correlates directly with the
intracellular cGMP concentration as shown elsewhere [16].
2.6. Western blotting
The expression of the transiently transfected wild-type (WT)-,
b1D44A-, b1D45A-, b1F74A-, b1I145A- and b1I145Y-sGC constructs
was validated by Western blot. Transfection was performed as
described above. 24 h after transfection, 10 lg total protein of the
100000 · g supernatant was separated by SDS–PAGE (10%) and
transferred to nitrocellulose membrane [22,23]. The individual sGC
subunits were detected using polyclonal antibodies directed against epi-
topes of the a1 (Cayman, Tallinn, Estonia) and the b1 (kindly donated
by H.H.H.W. Schmidt, Melbourne, Australia) subunit. Actin was
detected by a monoclonal anti-b-actin antibody (Sigma, Taufkirchen,
Germany). Detection was performed by ECL method [24].
2.7. Statistics
The data are presented as mean values ± S.E.M., and GraphPad
Prism Software Version 4.02 (GraphPad Software Inc., San Diego,
USA) was used for curve ﬁtting and calculation of EC50 values.3. Results
3.1. Selection and screening of sGC variants
The generated sGC b1-variants were screened using a cGMP
reporter cell line, a CHO cell line stably transfected with the
cyclic nucleotide gated olfactory CNG2A-channel and cyto-
solic aequorin. Enzyme activity was measured as luminescence,
indicated in relative light units (RLUs), which correlate with
intracellular cGMP concentration [3,16]. The substituted resi-
dues within the heme-binding domain of sGC were selected
according to molecular models that were calculated based on
a published prokaryotic homologue of the sGC heme-binding
domain. All substitutions were veriﬁed by sequencing and
transiently transfected into the cGMP reporter cell for protein
expression (Fig. 1).3.2. WT-sGC
Cotransfection of cGMP reporter cells with a1- and b1-
cDNA resulted in an activation proﬁle characteristic for the
native, heme-containing enzyme. The NO-independent, but
hemedependent sGC-stimulator BAY 41-2272, activated the
enzyme concentration dependently with an EC50 of 416 nM.
In the presence of DEA/NO, the concentration response curve
was shifted leftwards and EC50 was lowered to 16 nM (Fig. 2A,on a homologous gas-sensing protein of T. tencongensis (1U55.pdb),
ues characterized in the present work. (B) Multiple sequence alignment
orresponds to the rat-b1sGC. Aspartates discussed forming hydrogen
drophobic residues lining the heme-pocket. Asterisks mark the heme-
ts accession number in brackets. The predicted secondary structure is
sent predicted a-helices, and TT represent turns.
c
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Table 1
Primers used to generate the desired substitutions
bb1Y2A 50-GCGGTACACCATGGCCGGTTTTGTGAACC-3 0
bb1F4A 50-CACCATGTACGGTGCTGTGAACCATGCCC-3 0
bb1V5A 50-CATGTACGGTTTTGCGAACCATGCCCTG-30
bb1V5G 50-CATGTACGGTTTTGGGAACCATGCCCTG-30
bb1L51G 50-CCAAAACCTATGACGGAGTGGCTGCTGCGAGC-3 0
bb1Y43A 50-CAGTTTCTTGTGAGAATAATCGCGGATCA-
TTCCAAAACCTATGAC-30
*bb1D44A 50-CTTGTGAGAATAATCTACGCCCATTCCAAAA-
CCTATGAC-30
*bb1D45A 50-GTGAGAATAATCTACGATGCCTCCAAAACCTA-
TGACTTG-30
bb1F70A 50-CCTGCAGATGGCTGGGAAGAT-30
bb1M73A 50-GCAGATGTTTGGGAAGGCGTTTTTCGT-
CTTCTGTC-30
*bb1F74A 50-CAGATGTTTGGGAAGATGGCATTCGTCT-
TCTGTCAAGAG-3 0
*bb1F74Y 50-GATGTTTGGGAAGATGTATTTCGTC-
TTCTGTCAAG-30
bb1F74L 50-GATGTTTGGGAAGATGCTTTTCGTCTTCTGTC-3 0
bb1F75A 50-GATGTTTGGGAAGATGTTTGCCGTCTTCT-
GTCAAGAGTC-30
bb1F77A 50-GGGAAGATGTTCTTCGTCGCATGTCAAGAG-
TCTGGCTATG-30
bb1C78A 50-GATGTTTTTCGTCTTCGCTCAAGAGTCTGG-
CTATG-30
bb1Y83A 50-CTTCTGTCAAGAGTCTGGCGCAGATACCA-
TCTTGCGTGTC-3 0
bb1I86A 50-CTGGCTATGATACCGCCTTGCGTGTCCTG-3 0
bb1F97A 50-GATCTAATGTCAGGGAGGCTTTGCAGAA-
CCTCGAC-30
bb1L101A 50-GAGTTTTTGCAGAACGCAGACGCCCTGCACGAC-30
bb1L104A 50-GAACCTCGACGCCGCACACGACCACCTC-30
bb1L108A 50-CTGCACGACCACGCAGCCACCATCTAC-30
bb1Y112A 50-CTCGCCACCATCGCACCAGGGATGCG-3 0
bb1P118G 50-CCAGGGATGCGCGCAGGTTCCTTCCGGTGCACC-30
bb1Y133A 50-GGATGCGCGCACCTTCCGCACGGTGCA-
CCGATGCAG-30
bb1Y2A 50-GCAAAGGGCTCATTGCGCACTACTACTCGG-30
*bb1I145A 50-GAGGGGCTTCAGGACGCTGTGATCGGGATTATC-30
*bb1I145Y 50-GAGGGGCTTCAGGACTATGTGATCGGGATTATC-30
bb1I148A 50-CAGGACATTGTGATCGCGATTATCAAGACTGTAG-30
bb1I149A 50-GACATTGTGATCGGGAATATCAAGACTGTAGC-3 0
bb1I149A/I150A 50-CAGGACATTGTGATCGGAGCTGCTAAGAC-
TGTAGCTCAAC-3 0
bb1V146A 50-GGCTTCAGGACATTGCGATCGGGATTATCAAG-3 0
bb1Y192F 50-CAAAAGAAGAGGATTTTGTCGAAGATCTG-
GACAGGTTTG-30
The activation proﬁle of sGC-mutants was characterized by transient
transfection into the cGMP readout cell line. Mutants discussed in this
paper in detail are marked by an asterisk.
4208 C. Rothkegel et al. / FEBS Letters 580 (2006) 4205–4213Table 2). In the presence of the selective sGC inhibitor ODQ,
the eﬀect of BAY 41-2272 was nearly abolished. DEA/NO acti-
vated the enzyme with an EC50 of 27 nM and addition of 1 lM
BAY 41-2272 potentiated the activation to a maximum of 24-
fold and reduced the EC50 to 0.9 nM (Fig. 3A). The NO-and
heme-independent sGC activator BAY 58-2667, activated the
enzyme to a maximum of 10-fold, which was increased up to
15-fold in combination with DEA/NO (10 nM) and potentiated
up to 35-fold in the presence of ODQ (10 lM) (Fig. 2B, Table
2). Thus the activation proﬁle of the cGMP cells transiently
transfected with the native enzyme is similar to that observed
for the isolated sGC.3.3. b1D44A-sGC
The generated b1D44A sGC variant was not activated by
BAY 41-2272 either alone or in combination with DEA/NO(Fig. 2C). In contrast, this enzyme could be activated by
BAY 58-2667 with an EC50 of 2.9 lM. Additional ODQ
(10 lM) or DEA/NO (10 nM) (Fig. 2D) had no eﬀect. The loss
of responsiveness towards the heme-dependent sGC stimulator
BAY 41-2272 and DEA/NO, as well as the lack of eﬀect of
ODQ, indicate the loss of the prosthetic heme-moiety.
3.4. b1D45A-sGC
To test the hypothesis that b1D45 is involved in the mecha-
nism of sGC activation, the aspartate was exchanged with ala-
nine. The b1D45A-sGC variant was responsive to BAY 58-2667
with a maximal activation of 35-fold. This activation was only
slightly altered by ODQ or DEA/NO (Fig. 2F). In addition,
this enzyme showed a loss of responsiveness towards BAY
41-2272 and DEA/NO, indicating the loss of the prosthetic
heme moiety. Surprisingly, the combination of both heme-
dependent sGC stimulators resulted in a strong activation of
this sGC variant. In the presence of DEA/NO (10 nM), BAY
41-2272 induced a concentration dependent enzyme activation
with an EC50 of 0.6 lM (Fig. 2E). Vice versa, incubation with
DEA/NO in the presence of a ﬁxed concentration of BAY 41-
2272 (1 lM), resulted in a concentration dependent sGC acti-
vation with an EC50 of 4.4 nM (Fig. 3B). These results clearly
indicate that the b1D45A sGC is expressed as a heme-contain-
ing enzyme suggesting that the lack of enzyme activation by
DEA/NO or BAY 41-2272 alone might be due to an inter-
rupted intramolecular signal transmission.
3.5. b1F74A-sGC and b1F74Y-sGC
The b1F74A substitution virtually abolished enzyme activa-
tion by BAY 41-2272 alone or when combined with DEA/
NO (Table 2, Fig. 2G). In contrast, the b1F74Y mutant was
weakly activated by BAY 41-2272 to a maximum of 4-fold,
which was further potentiated in the presence of DEA/NO
(Fig. 2I). Both substitutions were responsive to BAY 58-2667
with EC50 values of 414 and 57 nM, respectively (Fig. 2H
and K). The BAY 58-2667-induced activation was enhanced
in the presence of ODQ (10 lM) for the b1F74Y mutant only.
Moreover, the maximal activation of the enzyme induced by
BAY 58-2667 is similar to that observed with BAY 58-2667
at the native enzyme in the presence of ODQ.
3.6. b1I145A-sGC and b1I145Y-sGC
Both enzyme variants showed an activation proﬁle similar to
the WT enzyme. BAY 41-2272 activated the b1IIe145A sGC
concentration dependently with an EC50 of 1 lM and the
b1I145Y with an EC50 of 0.4 lM (Table 2). DEA/NO potenti-
ated BAY 41-2272-induced activation in both mutants
(Fig. 4A and B). BAY 58-2667 induced a concentration depen-
dent activation of the b1I145A and b1I145Y enzyme variants to
a maximum of 4.8-fold and 6.5-fold, respectively that was
slightly increased by additional ODQ to 7.8-fold and 8.6-fold
(Fig. 4C and D).
3.7. Other mutants
All other mutants screened showed an activation proﬁle sim-
ilar to that of the WT enzyme (Table 1).
3.8. Western blot
To validate the expression of the diﬀerent constructs and to
determine the relative amounts of expressed enzyme compared
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Fig. 2. Activation pattern of WT- sGC (A, B) and mutant b1D44A-,
b1D45A-, b1F74A- and b1F74Y-sGC (C–K) incubated with increasing
concentrations of BAY 41-2272 or BAY 58-2667 alone or in the
presence of a ﬁxed concentration DEA/NO (10 nM) or ODQ (10 lM),
respectively. cGMP reporter cells were transiently cotransfected with
the WT a1-subunit and WT or mutated b1-subunit of sGC. Enzyme
activation is represented as x-fold compared with the transfected but
not stimulated control. Data are shown as means ± S.E.M. from 3–6
independent experiments performed in quadruple.
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rected against the C-termini of each subunit [25]. After lysis of
the cells we could detect both subunits in the 100000 · g super-
natant, whereas these subunits were apparently absent in
untransfected control cells (Fig. 5).4. Discussion
This study provides further insight into the regulation of
sGC activation by investigating the role of distinct sGC amino
acids potentially involved in this signaling process. Recently,
we identiﬁed the unique sGC heme binding motif, Y–x–S–x–
R, using a novel cGMP reporter cell line together with the
NO-independent, but heme-dependent sGC stimulator BAY
41-2272 and the NO- and heme-independent sGC activator
BAY 58-2667 [3,4,16]. The subsequent conﬁrmation of these
results via crystallization studies on homologous proteins,
highlights the usefulness of this indirect, but non-invasive, ap-
proach to directly characterize sGC substitutions in their na-
tive cellular environment without the need for further
puriﬁcation [5,6]. Based on our homology model of rat sGC,
the homology model reported by Boon et al. and multiple se-
quence alignments, amino acids which might be involved in the
intramolecular signaling process of sGC activation were se-
lected and screened [17]. Our model, as all protein models with
low homology to the template structure, is not reliable in struc-
tural detail. In addition, the model describes only a small part
of sGC, leaving open the spatial relationship between the heme
binding domain, the catalytic site and the predicted binding
sites for sGC stimulators and sGC activators. Therefore we
did not attempt to deduce an activation mechanism from our
homology model.
Our homology model indicated that b1Arg139, as part of
the sGC Y–x–S–x–R heme-binding motif, could form a side-
chain hydrogen bond with b1Asp45 [3–5]. Pellicena and
coworkers proposed that b1Asp45 plays a crucial role in sens-
ing the intramolecular distortion of the heme moiety and the
positioning of the heme propionic groups [5]. Conforma-
tional changes were suggested upon NO binding to the heme
iron [26–28]. Therefore diﬀerent NO-induced structural alter-
ations might converge in a movement of b1Asp45 suggesting
that this residue may function as intrinsic switch between dif-
ferent protein conformations reﬂecting the sGC activation
states [5].
To test this hypothesis we replaced b1Asp45 by alanine. The
resulting enzyme variant showed the typical activation pattern
of heme-free sGC; namely the BAY 58-2667-induced sGC
activation was not potentiated by ODQ and neither the
heme-dependent sGC stimulator BAY 41-2272 nor NO had
any eﬀect. However, to our surprise, the combination of NO
and BAY 41-2272 as well as NO and YC-1 (data not shown),
caused a concentration-dependent enzyme activation that was
even stronger than that observed for the native enzyme. This
clearly demonstrates that the b1Asp45 mutant is expressed as
a heme-containing enzyme but with an impaired signaling
mechanism for NO and heme-dependent stimulators such as
BAY 41-2272 or YC-1. Previous work has shown that the
heme-dependent sGC stimulator BAY 41-2272 sensitizes
sGC for NO [12,15]. The restoration of sGC activation by
the combination of BAY 41-2272 and NO may indicate that
the BAY 41-2272 is able to restore, in part, NO-derived sGC
activation by mimicking a still unknown function, usually car-
ried out by b1Asp45. These ﬁndings are in agreement with the
putative role of b1Asp45 in the NO derived sGC activation sug-
gested by Pellicena and coworkers [5]. However, further re-
search is needed to clarify the role of b1Asp45. Exchange of
the neighboring aspartate to b1Asp45, b1Asp44 resulted in an
enzyme displaying the typical activation pattern of heme-free
Table 2
WT- and diﬀerent mutant-sGC were expressed in the cGMP reporter cell and activated by BAY 41-2272 or BAY 58-2667 in a concentration range
from 1 nM to 30 lM
Mutant Control +DEA/NO (10 nM) +ODQ (10 lM)
EC50 x-fold EC50 x-fold EC50 x-fold
BAY 41-2272 (1 nM to 30 lM)
WT 416 ± 42 14.3 ± 0.1 16 ± 4.4 14.9 ± 0.16 n.d. 2.1 ± 0.05
bb1-D44A n.d. 1 ± 0.01 n.d. 1 ± 0.01 n.d. 1 ± 0.03
bb1-D45A n.d. 1.25 ± 0.01 640 ± 40 31.7 ± 0.15 n.d. 1 ± 0.08
bb1-F74A n.d. 1 ± 0.04 n.d. 1.6 ± 0.1 n.d. 1.6 ± 0.09
bb1-F74Y 837 ± 92 4.75 ± 0.02 4.1 ± 0.7 9.3 ± 0.13 n.d. 1.2 ± 0.06
bb1-I145A 1000 ± 16.5 7.7 ± 0.04 96 ± 5 10.3 ± 0.06 n.d. 2 ± 0.01
bb1-I145Y 430 ± 22.3 5.6 ± 0.05 46 ± 11 10.5 ± 0.04 n.d. 1.3 ± 0.01
BAY 58-2667 (1 nM to 30 lM)
WT 97 ± 13.9 11.2 ± 0.03 43 ± 17.7 17.6 ± 0.2 9.7 ± 2.5 35.2 ± 0.2
bb1-D44A 2910 ± 25 14.1 ± 0.2 2790 ± 63 14.7 ± 0.15 1820 ± 365 13.5 ± 0.2
bb1-D45A 634 ± 105 32.2 ± 0.13 350 ± 19 24.6 ± 0.06 560 ± 104 28.8 ± 0.06
bb1F74A 414 ± 64 30.3 ± 0.3 690 ± 83 31.6 ± 0.2 317 ± 56 30.0 ± 0.1
bb1-F74Y 57 ± 5 8.3 ± 0.03 55 ± 2 12.3 ± 0.03 50 ± 3 21.8 ± 0.1
bb1-I145A 23 ± 2.4 4.8 ± 0.2 15 ± 1.3 7.8 ± 0.06 7.6 ± 1.8 9.9 ± 0.03
bb1-I145Y 86 ± 2.9 6.5 ± 0.03 47 ± 4.3 8.6 ± 0.02 72 ± 1.7 7.6 ± 0.07
Both compounds were applied alone or combined with ﬁxed concentrations of DEA/NO (10 nM) and ODQ (1 lM). The table shows the determined
EC50 values in nM for both compounds and the x-fold activation of the enzymes compared to the basal state. Data are means ± S.E.M of 3–8
independent experiments performed in quadruple.
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Fig. 3. Concentration response curve of WT-SG (A) and b1D45A-sGC (B) incubated with increasing concentrations of DEA/NO alone or in the
presence of a ﬁxed concentration of BAY 41-2272 (1 lM). Data are means ± S.E.M. from 3 independent experiments performed in quadruples. sGC
activation is represented as x-fold compared to the transfected but not stimulated control.
4210 C. Rothkegel et al. / FEBS Letters 580 (2006) 4205–4213sGC. BAY 41-2272 and NO alone, or upon combination,
failed to activate the enzyme. In addition, BAY 58-2667-in-
duced enzyme activation was not enhanced by ODQ within
the cGMP reporter cell. Controlling expression of sGC sub-
units by Western blot analysis revealed no decrease of enzyme
expression of the b1Asp44Ala and other enzyme variants. The
activation proﬁle of the b1Asp44 sGC could be explained by
loss of the prosthetic heme moiety. However, as this residue
is in the direct vicinity of b1Asp45, which seems to be important
for intramolecular signal transduction, the ﬁndings might also
point out to an important function of this residue within the
process of enzyme activation.
Recent studies using the isolated sGC heme domain (b1 1–
385) suggest that a distal Tyr within the heme pocket is a pre-
requisite for oxygen binding [17,29]. In addition to the Tyr140
two further residues, Asn74 and Gln9, were proposed to be in-volved in forming a hydrogen bonding network triade to stabi-
lize the bound oxygen in T. tencongensis [5]. The authors
assume that these residues, especially Tyr140 are responsible
for the discrimination between NO and O2 [17,29]. In sGC
these residues are replaced by IIe145, Phe74 and Leu9. Whether
these diﬀerences result in abolition of the O2-sensing capability
or evolve to actively enhance the NO-sensing capability is still
a matter of debate. Therefore, we exchanged the corresponding
residues b1Ile145 and b1Phe74, to investigate their impact on the
NO-mediated sGC activation.
Exchange of b1Phe74 by Ala resulted in an enzyme showing
the typical activation pattern of heme-free sGC. In contrast,
exchange of b1Phe74 by Tyr resulted in an activation proﬁle
similar to that of WT-sGC. The data indicate that b1Phe74
appears to be important for heme-mediated sGC activation.
Our homology model of rat sGC revealed that b1Phe74 lies
C. Rothkegel et al. / FEBS Letters 580 (2006) 4205–4213 4211on the distal side of the heme-pocket opposing b1His105. Pub-
lished binding models suggest that NO binding to the pros-
thetic heme-moiety may partly occur on the opposite site of
b1His105 [26,30]. Therefore, it is tempting to speculate that
b1Phe74 may contribute to NO-mediated sGC activation. Reg-
ulation and discrimination of ligand binding to the heme moi-
ety by the chemical makeup of the heme pocket has been
described for heme proteins [31–35]. However, further experi-
ments are needed to clarify the contribution of b1Phe74 to
heme-dependent sGC stimulation.β1Ile145A
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Fig. 4. Activation pattern of b1IIe145A-sGC (A, B) and b1IIe145Y-sGC (C, D)
2667 alone or in the presence of a ﬁxed concentration DEA/NO (10 nM)
cotransfected with the a1-subunit and mutated b1-subunit of sGC. Enzyme ac
stimulated control. Data are shown as means ± S.E.M. from 3–6 independen
Fig. 5. Immunoblots of the cytosolic fractions of control and transiently a1
using polyclonal antibodies as described in Section 2. Lane 1, 10 lg cytosoli
sGC puriﬁed from Sf9 cells; lane 3, 10 lg cytosolic fraction of: WT-sGC; la
b1I145A-sGC; lane 8, b1I145Y-sGC transiently transfected cGMP reporter cells
(B) Primary antibody directed against the b1-subunit of rat lung sGC. ImmuIn a recent study, Boon et al. described the construction of
an O2-sensing sGC by introducing the polar OH group of a
tyrosine into the mainly hydrophobic heme-binding site
[17,29]. To test the functional properties of such an O2-sensing
sGC we constructed and screened the described sGC variant.
However, exchange of b1Ile145, which corresponds to the
Tyr140 residue in T. tencongensis, by Tyr caused no signiﬁcant
alteration of the activation proﬁle of the sGC mutant enzyme
compared to the native enzyme. Spectroscopic data presented
by Boon and coworkers suggested that b1I145Y-sGC is capableβ1Ile145A
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4212 C. Rothkegel et al. / FEBS Letters 580 (2006) 4205–4213of oxygen binding, although the reported KD value of 70 mM
questions the biological relevance of this ﬁnding. Under phys-
iological conditions, the concentration ratio between O2 and
NO is approximately 4 orders of magnitude. To discriminate
for NO in such an environment, the sGC heme-binding pocket
was optimized during evolution to exclude O2 and facilitate
NO-binding. Therefore, especially as the present study was
performed under normal atmospheric conditions (1 atm, 21%
O2) and only very low concentrations of NO were applied,
we expected that the introduction of the ‘‘assumed to be’’
NO/O2 switch would result in an alteration of the activation
proﬁle of the b1I145Y-sGC [17].
However, the b1I145Y-mutant showed an unchanged activa-
tion by NO which was comparable to the native enzyme.
Moreover, the heme oxidant ODQ potentiated the BAY 58-
2667 induced activation, suggesting no signiﬁcant autooxida-
tion of the mutant enzyme. Therefore, our data indicate that
introduction of a polar residue into the heme pocket does
not result in oxygen binding sGC, at least under atmospheric
conditions.
Ligand stabilization by a Tyr in the distal heme pocket has
been described for various hemoglobins [36]. In the light of
the published results, the ﬁnding that introduction of a polar
residue into the heme pocket of sGC causes no alteration of
sGC activation might be explained by the fact that the studies
performed by Boon and coworkers used only enzyme frag-
ments of sGC (b1 1–385) [17,29]. These fragments were spec-
troscopically characterized and measurement of the activity
of the complete mutated heterodimer of sGC has not been
performed to date. Moreover, the reported KD for oxygen
binding of 70 mM suggests that the b1I145Y-mutant sGC still
discriminates against oxygen [17]. In summary, these results
strongly suggest that the O2 binding capability of the HNOX
domain of T. tengcongensis arises as a consequence of multi-
ple adaptions of the heme-binding pocket rather than just the
introduction of a tyrosine. This view is supported by ﬁndings
describing the NO binding anaerobic sGC-like heme domain
of Clostridium botulinum. In spite of a Tyr residue within the
heme pocket, the enzyme appears to be incapable of oxygen
binding [6].
With respect to the heme vinyl groups, early studies showed
that the substitution of these groups with less hydrophobic or
even charged groups, disturbs the binding of the prosthetic
group to sGC [37]. However, a complete exchange of hydro-
phobic amino acids lining the heme-pocket in close proximity
to the vinyl groups, revealed no alteration of the sGC activa-
tion proﬁle (data not shown, Table 1). These ﬁndings suggest
that the vinyl groups, although they might contribute to the
binding of the heme moiety, do not play a crucial role in intra-
molecular sGC signaling as proposed for other heme proteins
[34].
It would be useful to determine if the mutant enzymes de-
scribed above are expressed as heme-containing or heme-free
proteins. Optical absorption spectra would be the only direct
way to assess heme-status, however, recording of the spectra
requires highly puriﬁed enzyme. It has been published that
during the puriﬁcation procedure of sGC artiﬁcial heme loss
may occur [38]. This problem becomes even more serious for
substitutions within the heme-binding pocket which could af-
fect the aﬃnity of the prosthetic group to the enzyme. One
way to overcome these obstacles could be via the non-invasive
measurement of the sGC heme state by spectroscopy within in-tact cells. However, since sGC represents only a small fraction
of the intracellular pool of heme proteins it appears impossible
to determine the sGC heme content using non-invasive spec-
troscopy. Immunoprecipitation of sGC with speciﬁc antibodies
and subsequent recording of spectra also requires cell lysis
resulting in the same problems described above for the puriﬁ-
cation of sGC. Therefore, in our opinion, the non-invasive
indirect approach used in the present paper is the best way
to characterize substitutions within the heme-binding site of
sGC.
In summary, we were able to show that b1Asp44, b1Asp45
and b1Phe74 are critical for sGC signaling. We conﬁrmed the
postulated role of b1Asp45 as a switch between diﬀerent sGC
conformations. Restoration of sGC activity via the combina-
tion of heme-dependent sGC stimulators such as BAY 41-
2272 and NO provide further insight into the mechanism of
action of this substance class. Moreover, our data indicate that
introduction of a polar residue into the heme pocket of sGC
does not result in an oxygen binding enzyme. However, crys-
tallization and cocrystallization studies with sGC, sGC stimu-
lators and sGC activators are required to conﬁrm the results of
the present study. Meanwhile, screening sGC mutants by using
the cGMP reporter cell in combination with the sGC stimula-
tor BAY 41-2272 and the sGC activator BAY 58-2667 is a
valuable approach to further elucidate the mechanism of
sGC activation.Acknowledgements: We are grateful to Thao-Vi Dao and Stefanie Ber-
hausen for the outstanding technical assistance, and Dr. Barbara
Kemp-Harper for critical comments on the manuscript. Peter M.
Schmidt is recipient of an Alexander-von-Humboldt Lynen fellowship.References
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